Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD
Introduction and objectives: Metabolic-associated fatty liver disease (MAFLD) is defined by steatosis in more than 5% of hepatocytes without other liver diseases. Patients with this disease can progress to multiple stages like liver fibrosis, cirrhosis, and hepatocellular carcinoma. miRNAs are singl...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-11-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268122000989 |
| _version_ | 1811194343882489856 |
|---|---|
| author | Guillermo N. López-Sánchez Eduardo Montalvo-Javé Mayra Domínguez-Perez Barbara Antuna-Puente Fredy O. Beltrán-Anaya Alfredo Hidalgo-Miranda Norberto C. Chávez-Tapia Misael Uribe Natalia Nuño- Lámbarri |
| author_facet | Guillermo N. López-Sánchez Eduardo Montalvo-Javé Mayra Domínguez-Perez Barbara Antuna-Puente Fredy O. Beltrán-Anaya Alfredo Hidalgo-Miranda Norberto C. Chávez-Tapia Misael Uribe Natalia Nuño- Lámbarri |
| author_sort | Guillermo N. López-Sánchez |
| collection | DOAJ |
| description | Introduction and objectives: Metabolic-associated fatty liver disease (MAFLD) is defined by steatosis in more than 5% of hepatocytes without other liver diseases. Patients with this disease can progress to multiple stages like liver fibrosis, cirrhosis, and hepatocellular carcinoma. miRNAs are single-stranded molecules that regulate metabolic homeostasis; their differential expression postulates them as potential circulating biomarkers for MAFLD. Previous research reported that hsa-miR-140-5p, hsa-miR-148-5p, and hsa-miR-122-3p have a differential expression in patients with MAFLD. This study aimed to investigate the correlation between liver hsa-miR-140-5p, hsa-miR-148-5p, and hsa-miR-122-3p and serum biomarkers CK-18, APOB, IL-6, IL-32, and TNF-α in patients with MAFLD compared with control patients. Materials and methods: A cross-sectional study was carried out with 16 patients of both sexes, aged between 18-60 years, to determine the association between the levels of hsa-miR-140-5p, hsa-miR-148-5p, and hsa-miR-122-3p with MAFLD in liver biopsies of patients who underwent laparoscopic cholecystectomy. Results: Twelve patients presented MAFLD, four without hepatic steatosis. Circulating levels of CK-18 showed a significant difference in patients with MAFLD, and a strong correlation was found between hsa-miR-122-3p, hsa-miR-140-5p, and hsa-miR-148b-5p versus the CAP value. Conclusion: There is a correlation between elevated tissue expression of hsa-miR-122-3p, hsa-miR-140-5p, and hsa-miR-148b-3p with plasma levels of CK-18 in patients with simple steatosis compared with patients without the disease. |
| first_indexed | 2024-04-12T00:24:12Z |
| format | Article |
| id | doaj.art-5f6329d02ae942fbae485c32750b791e |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-04-12T00:24:12Z |
| publishDate | 2022-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-5f6329d02ae942fbae485c32750b791e2022-12-22T03:55:34ZengElsevierAnnals of Hepatology1665-26812022-11-01276100756Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLDGuillermo N. López-Sánchez0Eduardo Montalvo-Javé1Mayra Domínguez-Perez2Barbara Antuna-Puente3Fredy O. Beltrán-Anaya4Alfredo Hidalgo-Miranda5Norberto C. Chávez-Tapia6Misael Uribe7Natalia Nuño- Lámbarri8Traslational Research Unit, Medica Sur Clinic & Foundation, Mexico City, MexicoDepartment of Surgery, Faculty of Medicine, The National Autonomous University of Mexico (UNAM), Mexico City, Mexico; Hepato Pancreato and Biliary Clinic, Department of General Surgery, “Hospital General de Mexico”, Dr. Eduardo Liceaga. Mexico City, Mexico; Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Mexico City, MexicoGenomics of Cardiovascular Diseases Laboratory, National Institute of Genomic Medicine, Mexico City, MexicoInfection Disease Division, Department of Medicine, Queen's University, Kingston, ON, CanadaVirology Laboratory, Faculty of Chemical Biological Sciences, UAGro. Lázaro CárdenasGenomics of Cancer Diseases Laboratory, National Institute of Genomic Medicine. Mexico City, MexicoTraslational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Mexico City, MexicoObesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Corresponding authors.Traslational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Corresponding authors.Introduction and objectives: Metabolic-associated fatty liver disease (MAFLD) is defined by steatosis in more than 5% of hepatocytes without other liver diseases. Patients with this disease can progress to multiple stages like liver fibrosis, cirrhosis, and hepatocellular carcinoma. miRNAs are single-stranded molecules that regulate metabolic homeostasis; their differential expression postulates them as potential circulating biomarkers for MAFLD. Previous research reported that hsa-miR-140-5p, hsa-miR-148-5p, and hsa-miR-122-3p have a differential expression in patients with MAFLD. This study aimed to investigate the correlation between liver hsa-miR-140-5p, hsa-miR-148-5p, and hsa-miR-122-3p and serum biomarkers CK-18, APOB, IL-6, IL-32, and TNF-α in patients with MAFLD compared with control patients. Materials and methods: A cross-sectional study was carried out with 16 patients of both sexes, aged between 18-60 years, to determine the association between the levels of hsa-miR-140-5p, hsa-miR-148-5p, and hsa-miR-122-3p with MAFLD in liver biopsies of patients who underwent laparoscopic cholecystectomy. Results: Twelve patients presented MAFLD, four without hepatic steatosis. Circulating levels of CK-18 showed a significant difference in patients with MAFLD, and a strong correlation was found between hsa-miR-122-3p, hsa-miR-140-5p, and hsa-miR-148b-5p versus the CAP value. Conclusion: There is a correlation between elevated tissue expression of hsa-miR-122-3p, hsa-miR-140-5p, and hsa-miR-148b-3p with plasma levels of CK-18 in patients with simple steatosis compared with patients without the disease.http://www.sciencedirect.com/science/article/pii/S1665268122000989microRNAMetabolic dysregulationBiomarkersLiver |
| spellingShingle | Guillermo N. López-Sánchez Eduardo Montalvo-Javé Mayra Domínguez-Perez Barbara Antuna-Puente Fredy O. Beltrán-Anaya Alfredo Hidalgo-Miranda Norberto C. Chávez-Tapia Misael Uribe Natalia Nuño- Lámbarri Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD Annals of Hepatology microRNA Metabolic dysregulation Biomarkers Liver |
| title | Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD |
| title_full | Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD |
| title_fullStr | Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD |
| title_full_unstemmed | Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD |
| title_short | Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD |
| title_sort | hepatic mir 122 3p mir 140 5p and mir 148b 5p expressions are correlated with cytokeratin 18 serum levels in mafld |
| topic | microRNA Metabolic dysregulation Biomarkers Liver |
| url | http://www.sciencedirect.com/science/article/pii/S1665268122000989 |
| work_keys_str_mv | AT guillermonlopezsanchez hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT eduardomontalvojave hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT mayradominguezperez hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT barbaraantunapuente hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT fredyobeltrananaya hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT alfredohidalgomiranda hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT norbertocchaveztapia hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT misaeluribe hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld AT natalianunolambarri hepaticmir1223pmir1405pandmir148b5pexpressionsarecorrelatedwithcytokeratin18serumlevelsinmafld |